{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:06:43Z","timestamp":1792516003994,"version":"4.5.0"},"reference-count":300,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178198","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:04:36Z","timestamp":1758938676000},"page":"178198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Small interfering RNA (siRNA) based therapies for cancer treatment: A special focus on cervical cancer"],"prefix":"10.1016","volume":"1007","author":[{"given":"Labdhi","family":"Bavishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital B.","family":"Butani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehal S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.ejphar.2025.178198_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab030","article-title":"Ligand-mediated delivery of RNAi-Based therapeutics for the treatment of oncological diseases","volume":"3","author":"Abdelaal","year":"2021","journal-title":"NAR Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab030","article-title":"Ligand-mediated delivery of RNAi-Based therapeutics for the treatment of oncological diseases","volume":"3","author":"Abdelaal","year":"2021","journal-title":"NAR Cancer"},{"issue":"16","key":"10.1016\/j.ejphar.2025.178198_bib4","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.3390\/ijms25169086","article-title":"CRISPR\/Cas-Mediated knockdown of PD-L1 and KRAS in lung cancer cells","volume":"25","author":"Abounar","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40001-023-01014-9","article-title":"SiRNA-E6 sensitizes HPV-16-Related cervical cancer through oxaliplatin: an in vitro study on anti-cancer combination therapy","volume":"28","author":"Aghbash","year":"2023","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/nar\/gkg147","article-title":"Tolerance for mutations and chemical modifications in a SiRNA","volume":"31","author":"Amarzguioui","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178198_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","article-title":"Targeted SiRNA lipid nanoparticles for the treatment of KRAS-mutant tumors","volume":"357","author":"Anthiya","year":"2023","journal-title":"J. Contr. Release"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.gt.3302726","article-title":"Target selectivity in MRNA silencing","volume":"13","author":"Aronin","year":"2006","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3390\/cancers12051301","article-title":"Targeted gene delivery therapies for cervical cancer","volume":"12","author":"\u00c1yen","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15012-5","article-title":"Chemodrug delivery using integrin-targeted PLGA-chitosan nanoparticle for lung cancer therapy","volume":"7","author":"Babu","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","article-title":"Editorial focus: understanding off-Target effects as the key to successful RNAi therapy","volume":"24","author":"Bartoszewski","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050028","article-title":"PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of Metalloproteinases-1 (TIMP-1)","volume":"7","author":"Batra","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s13346-020-00741-4","article-title":"Vaginal SiRNA delivery: overview on novel delivery approaches","volume":"10","author":"Baxi","year":"2020","journal-title":"Drug Deliv. Trans. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off\u2010target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/cells11101697","article-title":"Interaction of cationic carbosilane dendrimers and their SiRNA complexes with MCF-7 cells cultured in 3D spheroids","volume":"11","author":"Bia\u0142kowska","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178198_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jconrel.2022.07.041","article-title":"Engineered ionizable lipid SiRNA conjugates enhance endosomal escape but induce toxicity in vivo","volume":"349","author":"Biscans","year":"2022","journal-title":"J. Contr. Release"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/ph6020161","article-title":"Dendrimers for SiRNA delivery","volume":"6","author":"Biswas","year":"2013","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178198_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.omtn.2023.07.023","article-title":"Toward learning the rules that predict SiRNA efficacy","volume":"33","author":"Bofill-De Ros","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178198_bib20","first-page":"320","article-title":"Molecular pathways in the development of HPV-induced cervical cancer","volume":"20","author":"Bonab","year":"2021","journal-title":"EXCLI J."},{"issue":"19","key":"10.1016\/j.ejphar.2025.178198_bib21","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1158\/1078-0432.CCR-24-0385","article-title":"Cervical cancer evades the host immune system through the inhibition of type I interferon and CXCL9 by LIF","volume":"30","author":"Bonfill-Teixidor","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s12276-020-0407-z","article-title":"The emerging role of RNA modifications in the regulation of MRNA stability","volume":"52","author":"Boo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib23","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1261\/rna.5256704","article-title":"Xenopus U3 SnoRNA docks on Pre-RRNA through a novel base-pairing interaction","volume":"10","author":"Borovjagin","year":"2004","journal-title":"RNA"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib24","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3390\/ijms20092188","article-title":"PI3K\/AKT\/MTOR signaling regulates the virus\/host cell crosstalk in HPV-positive cervical cancer cells","volume":"20","author":"Bossler","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1038\/sj.onc.1210798","article-title":"High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells","volume":"27","author":"Bottley","year":"2008","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/mt.2011.185","article-title":"Rational design of therapeutic SiRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for huntington's disease","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gks797","article-title":"SiSPOTR: a tool for designing highly specific and potent SiRNAs for human and mouse","volume":"41","author":"Boudreau","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/pharmaceutics16040548","article-title":"LDLR-mediated targeting and productive uptake of SiRNA-Peptide ligand conjugates in vitro and in vivo","volume":"16","author":"Broc","year":"2024","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of MiRNAs and SiRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178198_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2019.10.046","article-title":"A novel small-molecule inhibitor of the human papillomavirus E6-P53 interaction that reactivates P53 function and blocks cancer cells growth","volume":"470","author":"Celegato","year":"2020","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/cgt.2010.38","article-title":"Highly potent and specific SiRNAs against E6 or E7 genes of HPV16- or HPV18-Infected cervical cancers","volume":"17","author":"Chang","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/cgt.2010.38","article-title":"Highly potent and specific SiRNAs against E6 or E7 genes of HPV16- or HPV18-Infected cervical cancers","volume":"17","author":"Chang","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/cgt.2010.38","article-title":"Highly potent and specific SiRNAs against E6 or E7 genes of HPV16- or HPV18-Infected cervical cancers","volume":"17","author":"Chang","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Accounts Chem. Res."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","article-title":"Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy","volume":"23","author":"Chehelgerdi","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2012.12.070","article-title":"Effect of SiRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents","volume":"431","author":"Chen","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"26","key":"10.1016\/j.ejphar.2025.178198_bib41","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1016\/j.biomaterials.2011.04.053","article-title":"Enhanced SiRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides","volume":"32","author":"Cheng","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2025.178198_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.omtn.2016.12.011","article-title":"Cholesterol-containing nuclease-resistant SiRNA accumulates in tumors in a carrier-free mode and silences MDR1 gene","volume":"6","author":"Chernikov","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178198_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of SiRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ijms24020956","article-title":"Structural modifications of SiRNA improve its performance in vivo","volume":"24","author":"Chernikov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib45","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"SiRNA function in RNAi: a chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.ejphar.2025.178198_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115306","article-title":"Advancing cancer immunotherapy through SiRNA-Based gene silencing for immune checkpoint blockade","volume":"209","author":"Choi","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178198_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.855019","article-title":"PH-Responsive polymer nanomaterials for tumor therapy","volume":"12","author":"Chu","year":"2022","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41419-022-05347-x","article-title":"Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer","volume":"13","author":"Coelho","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102429","article-title":"SiRNA tackles cancer: immune checkpoint inhibitors and SiRNA combinations","volume":"36","author":"Coles","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib50","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178198_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2019.07.010","article-title":"Peptide carriers to the rescue: overcoming the barriers to SiRNA delivery for cancer treatment","volume":"214","author":"Cummings","year":"2019","journal-title":"Transl. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of SiRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci. : IJBS"},{"key":"10.1016\/j.ejphar.2025.178198_bib53","first-page":"10","article-title":"Nanoparticle-based drug delivery systems for cancer therapy","volume":"1","author":"Dang","year":"2020","journal-title":"Smart Mater. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3390\/ph15050575","article-title":"Biotechnological evolution of SiRNA molecules: from bench tool to the refined drug","volume":"15","author":"de Brito e Cunha","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: a progress report on SiRNA-Based therapeutics","volume":"6","author":"de Fougerolles","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"10.1016\/j.ejphar.2025.178198_bib56","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.15252\/embj.201796438","article-title":"MYC and tumor metabolism: chicken and egg","volume":"36","author":"Dejure","year":"2017","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.ejphar.2025.178198_bib57","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1093\/nar\/gkq181","article-title":"Synergistic effects between analogs of DNA and RNA improve the potency of SiRNA-Mediated gene silencing","volume":"38","author":"Deleavey","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178198_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1175958","article-title":"Anti-HPV16 oncoproteins SiRNA therapy for cervical cancer using a novel transdermal peptide PKU12","volume":"13","author":"Deng","year":"2023","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5483\/BMBRep.2018.51.9.187","article-title":"The road less traveled: strategies to enhance the frequency of homology-directed repair (HDR) for increased efficiency of CRISPR\/Cas-Mediated transgenesis","volume":"51","author":"Devkota","year":"2018","journal-title":"BMB Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib60","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40364-024-00701-x","article-title":"State of the art CRISPR-based strategies for cancer diagnostics and treatment","volume":"12","author":"Di Carlo","year":"2024","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178198_bib61","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1242\/jcs.066399","article-title":"Breaking down the barriers: SiRNA delivery and endosome escape","volume":"123","author":"Dominska","year":"2010","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2025.178198_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108488","article-title":"Strategies to overcome cancer multidrug resistance (MDR) through targeting P-Glycoprotein (ABCB1): an updated review","volume":"249","author":"Dong","year":"2023","journal-title":"Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib63","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.coviro.2013.06.003","article-title":"Latent papillomavirus infections and their regulation","volume":"3","author":"Doorbar","year":"2013","journal-title":"Curr. Opin. Virol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib64","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: how do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA therapeutics: the great endosomal escape","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Therapeut."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib66","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/cas.14397","article-title":"In vitro and in vivo synergistic efficacy of Ceritinib combined with programmed cell death Ligand\u20101 inhibitor in anaplastic lymphoma kinase\u2010rearranged non\u2010small\u2010cell lung cancer","volume":"111","author":"Du","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/nar\/gki193","article-title":"Locked Nucleic Acid (LNA) mediated improvements in SiRNA stability and functionality","volume":"33","author":"Elm","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \u2018PEG Dilemma\u2019 in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/genes10020092","article-title":"RNA modifications modulate activation of innate toll-like receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib71","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/genes10020092","article-title":"RNA modifications modulate activation of innate toll-like receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/v9090252","article-title":"Analysis of class I major histocompatibility complex gene transcription in human tumors caused by human papillomavirus infection","volume":"9","author":"Gameiro","year":"2017","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib73","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in SiRNA therapeutics and synergistic effect on SiRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay","year":"2022","journal-title":"RNA Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib74","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The effect of chemical modification and nanoparticle formulation on stability and biodistribution of SiRNA in mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib75","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41417-021-00366-w","article-title":"The application of CRISPR\/Cas9 system in cervical carcinogenesis","volume":"29","author":"Gao","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejphar.2025.178198_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.598175","article-title":"Rationale and application of PEGylated lipid-based system for advanced target delivery of SiRNA","volume":"11","author":"Ge","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178198_bib77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178198_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2022.100074","article-title":"Insights into therapy resistance in cervical cancer","volume":"6","author":"George","year":"2022","journal-title":"Adv. Cancer Biol. Metastasis"},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib79","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/JVI.75.10.4705-4712.2001","article-title":"Induction of PRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome P16 INK4a -Imposed G 1 cell cycle arrest","volume":"75","author":"Giarre","year":"2001","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib80","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/MTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2025.178198_bib81","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2022.06.005","article-title":"PK-Modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics SiRNAs","volume":"29","author":"Godinho","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2172-10-40","article-title":"Sequence determinants of innate immune activation by short interfering RNAs","volume":"10","author":"Goodchild","year":"2009","journal-title":"BMC Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib83","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cbdd.12052","article-title":"SiRNA delivery: from lipids to cell\u2010penetrating peptides and their mimics","volume":"80","author":"Gooding","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejphar.2025.178198_bib84","series-title":"Sirna and Shrna as Anticancer Agents in a Cervical Cancer Model","first-page":"159","author":"Gu","year":"2008"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.5732\/cjc.012.10280","article-title":"Small interfering RNA-based molecular therapy of cancers","volume":"32","author":"Guo","year":"2013","journal-title":"Chin. J. Cancer"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.5732\/cjc.012.10280","article-title":"Small interfering RNA-based molecular therapy of cancers","volume":"32","author":"Guo","year":"2013","journal-title":"Chin. J. Cancer"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib87","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.embor.7400660","article-title":"Warming up at the poles","volume":"7","author":"Hagan","year":"2006","journal-title":"EMBO Rep."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib88","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1021\/acs.bioconjchem.0c00520","article-title":"Enhancing combined immunotherapy and radiotherapy through nanomedicine","volume":"31","author":"Hagan","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejphar.2025.178198_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000355952","article-title":"Human papillomavirus genomics: past, present and future","volume":"45","author":"Harari","year":"2014","journal-title":"Curr. Probl. Dermatol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib90","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified SiRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib91","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bcp.2005.11.015","article-title":"Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of SiRNAs in serum","volume":"71","author":"Haupenthal","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"24","key":"10.1016\/j.ejphar.2025.178198_bib92","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.3390\/molecules25245963","article-title":"Cellular targeting of oligonucleotides by conjugation with small molecules","volume":"25","author":"Hawner","year":"2020","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/nrm2420","article-title":"Virus plays dead","volume":"9","author":"Heinrichs","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/oli.2008.0149","article-title":"Stability study of unmodified SiRNA and relevance to clinical use","volume":"18","author":"Hickerson","year":"2008","journal-title":"Oligonucleotides"},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib95","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.biotechadv.2015.05.005","article-title":"A role for peptides in overcoming endosomal entrapment in SiRNA delivery \u2014 a focus on melittin","volume":"33","author":"Hou","year":"2015","journal-title":"Biotechnol. Adv."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib96","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for MRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib97","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for MRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic SiRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic SiRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib100","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3892\/ol.2020.11754","article-title":"\u201ccervical cancer in low and middle-income countries","volume":"20","author":"Hull","year":"2020","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib101","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbagrm.2007.11.004","article-title":"RNA recognition by 3\u2032-to-5\u2032 exonucleases: the substrate perspective","volume":"1779","author":"Ibrahim","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) Gene Regulatory Mech."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib102","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acsomega.7b00291","article-title":"Chemical modification of the SiRNA seed region suppresses off-target effects by steric hindrance to base-pairing with targets","volume":"2","author":"Iribe","year":"2017","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71896-w","article-title":"An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves SiRNA stability","volume":"10","author":"Irie","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib104","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7150\/thno.5743","article-title":"Optimized SiRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice","volume":"3","author":"Iversen","year":"2013","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.molcel.2021.11.026","article-title":"Life of RISC: formation, action, and degradation of RNA-induced silencing complex","volume":"82","author":"Iwakawa","year":"2022","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding SiRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib107","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/nar\/gkab544","article-title":"Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo","volume":"50","author":"Jahns","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib108","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/nar\/gkab544","article-title":"Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology In Vivo","volume":"50","author":"Jahns","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib109","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13353-024-00883-y","article-title":"HPV-driven oncogenesis\u2014much more than the E6 and E7 oncoproteins","volume":"66","author":"Janiszewska","year":"2025","journal-title":"J. Appl. Genet."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-024-01749-9","article-title":"Protein translation: biological processes and therapeutic strategies for human diseases","volume":"9","author":"Jia","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib111","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ygyno.2008.06.033","article-title":"Gene silencing with SiRNA targeting E6\/E7 as a therapeutic intervention in a mouse model of cervical cancer","volume":"111","author":"Jonson","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib112","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ygyno.2008.06.033","article-title":"Gene silencing with SiRNA targeting E6\/E7 as a therapeutic intervention in a mouse model of cervical cancer","volume":"111","author":"Jonson","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2007.179","article-title":"Overcoming the innate immune response to small interfering RNA","volume":"19","author":"Judge","year":"2008","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib114","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of noninflammatory synthetic SiRNA mediating potent gene silencing in vivo","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.178198_bib115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib116","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/jcm4051126","article-title":"Human papillomavirus: current and future RNAi therapeutic strategies for cervical cancer","volume":"4","author":"Jung","year":"2015","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib117","doi-asserted-by":"crossref","first-page":"12243","DOI":"10.3390\/ijms160612243","article-title":"Human papillomavirus E6\/E7-Specific SiRNA potentiates the effect of radiotherapy for cervical cancer in vitro and in vivo","volume":"16","author":"Jung","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.ejphar.2025.178198_bib118","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib119","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/nat.2011.0298","article-title":"Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif","volume":"21","author":"Jurk","year":"2011","journal-title":"Nucleic Acid Therapeut."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib120","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"SiRNA functionalized lipid nanoparticles (LNPs) in management of diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib121","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib122","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","article-title":"Action and reaction: the biological response to SiRNA and its delivery vehicles","volume":"20","author":"Kanasty","year":"2012","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib123","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12935-022-02654-3","article-title":"CRISPR\/Cas9 system in breast cancer therapy: advancement, limitations and future scope","volume":"22","author":"Karn","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib124","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","article-title":"CRISPR in cancer biology and therapy","volume":"22","author":"Katti","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ddtec.2005.08.012","article-title":"Locked Nucleic Acid (LNA): high affinity targeting of RNA for diagnostics and therapeutics","volume":"2","author":"Kauppinen","year":"2005","journal-title":"Drug Discov. Today Technol."},{"issue":"20","key":"10.1016\/j.ejphar.2025.178198_bib126","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.ejphar.2025.178198_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316933","article-title":"Nucleic acid-based approaches to tackle KRAS mutant cancers","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib128","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.molmed.2009.09.001","article-title":"Strategies for targeted nonviral delivery of SiRNAs in vivo","volume":"15","author":"Kim","year":"2009","journal-title":"Trends Mol. Med."},{"issue":"31","key":"10.1016\/j.ejphar.2025.178198_bib129","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2010.32.9615","article-title":"Estrogen receptor (ESR1) MRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor\u2013positive breast cancer","volume":"29","author":"Kim","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102415","article-title":"Improving the potency prediction for chemically modified SiRNAs through insights from molecular modeling of individual sequence positions","volume":"36","author":"Kliuchnikov","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib131","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/genes13020319","article-title":"The SiRNA off-target effect is determined by base-pairing stabilities of two different regions with opposite effects","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib132","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1128\/JVI.01756-10","article-title":"A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions","volume":"85","author":"Kranjec","year":"2011","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib133","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/adt.2024.015","article-title":"A concise review on effect of PEGylation on the properties of lipid-based nanoparticles","volume":"22","author":"Krishnan","year":"2024","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejphar.2025.178198_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of lipid nanoparticles for SiRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy","volume":"3","author":"Kumar","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178198_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of SiRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178198_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of SiRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"23","key":"10.1016\/j.ejphar.2025.178198_bib137","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1021\/acsomega.3c01703","article-title":"Emergence of small interfering RNA-based gene drugs for various diseases","volume":"8","author":"Kurakula","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejphar.2025.178198_bib138","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"SiRNA versus MiRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178198_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1226336","article-title":"Machine learning for small interfering RNAs: a concise review of recent developments","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejphar.2025.178198_bib140","first-page":"1","article-title":"Recent developments in nanoparticle-based SiRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2025.178198_bib141","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2016.05.010","article-title":"Delivery strategies and potential targets for SiRNA in major cancer types","volume":"104","author":"Lee","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib142","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/JVI.79.3.1645-1654.2005","article-title":"Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape","volume":"79","author":"Leonard","year":"2005","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib143","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/sj.embor.7400637","article-title":"Cleavage of the SiRNA passenger strand during RISC assembly in human cells","volume":"7","author":"Leuschner","year":"2006","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib144","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canlet.2013.02.034","article-title":"Plasmid-based E6-Specific SiRNA and Co-Expression of wild-type P53 suppresses the growth of cervical cancer in vitro and in vivo","volume":"335","author":"Li","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib146","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12943-024-02215-4","article-title":"Emerging role of exosomes in cancer therapy: progress and challenges","volume":"24","author":"Li","year":"2025","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102344","article-title":"CRISPR-Cas9-Mediated homology-directed repair for precise gene editing","volume":"35","author":"Liao","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib148","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/nar\/gkw065","article-title":"RNA cleavage products generated by antisense oligonucleotides and SiRNAs are processed by the RNA surveillance machinery","volume":"44","author":"Lima","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178198_bib149","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jconrel.2023.07.007","article-title":"Genome editing MRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-Cell therapy","volume":"360","author":"Ling","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.178198_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00691","article-title":"Methodologies for improving HDR efficiency","volume":"9","author":"Liu","year":"2019","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib151","first-page":"570","article-title":"\u201cCurrent strategies against persistent human papillomavirus infection","volume":"55","author":"Liu","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2025.178198_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114065","article-title":"Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems","volume":"157","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib153","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.molmed.2005.01.005","article-title":"Modulation of angiogenesis with SiRNA inhibitors for novel therapeutics","volume":"11","author":"Lu","year":"2005","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.gpb.2018.03.002","article-title":"Applications of RNA indexes for precision oncology in breast cancer","volume":"16","author":"Ma","year":"2018","journal-title":"Genom. Proteom. Bioinform."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib155","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.3390\/molecules25112692","article-title":"Lipid and polymer-based nanoparticle SiRNA delivery systems for cancer therapy","volume":"25","author":"Mainini","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib156","doi-asserted-by":"crossref","DOI":"10.1142\/S179398441241005X","article-title":"Endocytosis pathways for nucleic acid therapeutics","volume":"2","author":"Malefyt","year":"2012","journal-title":"Nano LIFE"},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib157","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/anie.201006519","article-title":"Unique gene\u2010silencing and structural properties of 2\u2032\u2010Fluoro\u2010Modified SiRNAs","volume":"50","author":"Manoharan","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib158","first-page":"313","article-title":"RNA interference and its role in cancer therapy","volume":"4","author":"Mansoori","year":"2014","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib159","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41423-021-00792-8","article-title":"Protein synthesis, degradation, and energy metabolism in T cell immunity","volume":"19","author":"Marchingo","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygeno.2024.110815","article-title":"From sequences to therapeutics: using machine learning to predict chemically modified SiRNA activity","volume":"116","author":"Martinelli","year":"2024","journal-title":"Genomics"},{"key":"10.1016\/j.ejphar.2025.178198_bib161","article-title":"Machine learning for SiRNA efficiency prediction: a systematic review","volume":"11","author":"Martinelli","year":"2024","journal-title":"Health Sci. Rev."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib162","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/MCB.19.7.4672","article-title":"C-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points","volume":"19","author":"Mateyak","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.178198_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.178198_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2025.178198_bib165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/BTT.S429411","article-title":"Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing","volume":"18","author":"Mengstie","year":"2024","journal-title":"Biol. Targets & Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib166","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based SiRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib167","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4161\/adna.1.1.12204","article-title":"In vivo efficacy and off-target effects of Locked Nucleic Acid (LNA) and Unlocked Nucleic Acid (UNA) modified SiRNA and small internally segmented interfering RNA (SisiRNA) in mice bearing human tumor xenografts","volume":"1","author":"Mook","year":"2010","journal-title":"Artif. DNA PNA XNA"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib168","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41418-020-00693-9","article-title":"E6-Mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer","volume":"28","author":"Morgan","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178198_bib169","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1393646","article-title":"Principle, application and challenges of development SiRNA-Based therapeutics against bacterial and viral infections: a comprehensive review","volume":"15","author":"Motamedi","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2025.178198_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1393646","article-title":"Principle, application and challenges of development SiRNA-Based therapeutics against bacterial and viral infections: a comprehensive review","volume":"15","author":"Motamedi","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2025.178198_bib67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for SiRNA delivery in cancer treatment","volume":"361","author":"Moukhtari","year":"2023","journal-title":"J. Contr. Release"},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib171","article-title":"Alteration of the IFN-pathway by human papillomavirus proteins: antiviral immune response evasion mechanism","volume":"10","author":"Mu\u00f1oz","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib172","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rvsc.2007.03.012","article-title":"The effect of small interfering RNA (SiRNA) against the Bcl-2 gene on apoptosis and chemosensitivity in a canine mammary gland tumor cell line","volume":"84","author":"Nagamatsu","year":"2008","journal-title":"Res. Vet. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib173","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/1471-2105-10-392","article-title":"SiDirect 2.0: updated software for designing functional SiRNA with reduced seed-dependent off-Target effect","volume":"10","author":"Naito","year":"2009","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.ejphar.2025.178198_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2020.526455","article-title":"SiRNA specificity: RNAi mechanisms and strategies to reduce off-target effects","volume":"11","author":"Neumeier","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.ejphar.2025.178198_bib175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2016.03.016","article-title":"Systemic delivery of SiRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes","volume":"231","author":"Nishida","year":"2016","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib176","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/abbs\/gmu129","article-title":"Knockdown of C-Myc inhibits cell proliferation by negatively regulating the Cdk\/Rb\/E2F pathway in nasopharyngeal carcinoma cells","volume":"47","author":"Niu","year":"2015","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"34","key":"10.1016\/j.ejphar.2025.178198_bib177","doi-asserted-by":"crossref","first-page":"31263","DOI":"10.1074\/jbc.M202528200","article-title":"The proto-oncogene c-Myc acts through the cyclin-dependent kinase (Cdk) inhibitor P27Kip1to facilitate the activation of Cdk4\/6 and early G1Phase progression","volume":"277","author":"Obaya","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib178","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1136\/gut.2004.056192","article-title":"Variants of Bcl-2 specific SiRNA for silencing antiapoptotic Bcl-2 in pancreatic cancer","volume":"54","author":"Ocker","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib179","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving SiRNA delivery in vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.ejphar.2025.178198_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.882363","article-title":"Understanding the role and impact of Poly (Ethylene glycol) (PEG) on nanoparticle formulation: implications for COVID-19 vaccines","volume":"10","author":"Pad\u00edn-Gonz\u00e1lez","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.178198_bib181","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2025.178198_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2020","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178198_bib183","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1093\/nar\/gkq1270","article-title":"Unexpected origins of the enhanced pairing affinity of 2\u2032-Fluoro-Modified RNA","volume":"39","author":"Pallan","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib184","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178198_bib185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2015.12.004","article-title":"Pharmacokinetics and biodistribution of recently-developed SiRNA nanomedicines","volume":"104","author":"Park","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib186","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2407-10-204","article-title":"The SiRNA targeted to Mdr1b and Mdr1a MRNAs in vivosensitizes murine lymphosarcoma to chemotherapy","volume":"10","author":"Patutina","year":"2010","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib187","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib188","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/microorganisms13051000","article-title":"Molecular insights into HPV-driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications","volume":"13","author":"Pavelescu","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejphar.2025.178198_bib189","series-title":"Handbook of Chemical Biology of Nucleic Acids","first-page":"1","article-title":"Phosphorothioate nucleic acids: artificial modification envisaged by nature","author":"Paw\u0142owska","year":"2023"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib190","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/nar\/gkr1002","article-title":"Carrier-free cellular uptake and the gene-silencing activity of the lipophilic SiRNAs is strongly affected by the length of the linker between SiRNA and lipophilic group","volume":"40","author":"Petrova","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178198_bib191","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.7150\/thno.40889","article-title":"A combat with the YAP\/TAZ-TEAD oncoproteins for cancer therapy","volume":"10","author":"Pobbati","year":"2020","journal-title":"Theranostics"},{"issue":"14","key":"10.1016\/j.ejphar.2025.178198_bib192","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1093\/nar\/gkac618","article-title":"Insights into innate immune activation via PS-ASO\u2013Protein\u2013TLR9 interactions","volume":"50","author":"Pollak","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.ejphar.2025.178198_bib193","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1261\/rna.070813.119","article-title":"Ribosome clearance during RNA interference","volume":"25","author":"Pule","year":"2019","journal-title":"RNA"},{"issue":"21\u201322","key":"10.1016\/j.ejphar.2025.178198_bib194","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2008.06.008","article-title":"Maintaining the silence: reflections on long-term RNAi","volume":"13","author":"Raemdonck","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"21\u201322","key":"10.1016\/j.ejphar.2025.178198_bib195","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2008.06.008","article-title":"Maintaining the silence: reflections on long-term RNAi","volume":"13","author":"Raemdonck","year":"2008","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib196","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.neo.2017.07.005","article-title":"Effect of HPV E6\/E7 SiRNA with chemotherapeutic agents on the regulation of TP53\/E2F dynamic behavior for cell fate decisions","volume":"19","author":"Rajasekaran","year":"2017","journal-title":"Neoplasia"},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib197","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/D3MD00145H","article-title":"MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives","volume":"14","author":"Ram","year":"2023","journal-title":"RSC Med. Chem."},{"issue":"21","key":"10.1016\/j.ejphar.2025.178198_bib198","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development\u2014an introductory review","volume":"180","author":"Ranasinghe","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib199","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2005.10.020","article-title":"Argonaute2 cleaves the anti-guide strand of SiRNA during RISC activation","volume":"123","author":"Rand","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178198_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115052","article-title":"A holistic analysis of the intrinsic and delivery-mediated toxicity of SiRNA therapeutics","volume":"201","author":"Ranjbar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib201","doi-asserted-by":"crossref","first-page":"E85","DOI":"10.1152\/ajpendo.00422.2018","article-title":"Aging impairs mouse skeletal muscle macrophage polarization and muscle-specific abundance during recovery from disuse","volume":"317","author":"Reidy","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejphar.2025.178198_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01260","article-title":"PLGA-based nanoparticles in cancer treatment","volume":"9","author":"Rezvantalab","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib204","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.ejphar.2025.178198_bib205","article-title":"A graph neural network approach for the analysis of SiRNA-Target biological networks","volume":"23","author":"Rosa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib206","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for SiRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib207","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/cbic.201900630","article-title":"Impact of phosphorothioate chirality on double\u2010stranded SiRNAs: a systematic evaluation of stereopure SiRNA designs","volume":"21","author":"Sakamuri","year":"2020","journal-title":"Chembiochem"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.sbi.2009.12.001","article-title":"Structural insights into RNA interference","volume":"20","author":"Sashital","year":"2010","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib209","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001540","article-title":"The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation","volume":"102","author":"Scarth","year":"2021","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-22-2155","article-title":"RNA therapeutics for improving CAR T-Cell safety and efficacy","volume":"83","author":"Schaible","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib211","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/IGC.0b013e3181a83467","article-title":"A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix","volume":"19","author":"Schilder","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib212","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2796.2009.02189.x","article-title":"Lipid\u2010based nanotherapeutics for SiRNA delivery","volume":"267","author":"Schroeder","year":"2010","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2796.2009.02189.x","article-title":"Lipid\u2010based nanotherapeutics for SiRNA delivery","volume":"267","author":"Schroeder","year":"2010","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib214","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/pharmacy12020058","article-title":"A comparison of currently approved small interfering RNA (SiRNA) medications to alternative treatments by costs, indications, and medicaid coverage","volume":"12","author":"Sehgal","year":"2024","journal-title":"Pharmacy"},{"key":"10.1016\/j.ejphar.2025.178198_bib215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13027-016-0107-4","article-title":"Molecular mechanisms of HPV mediated neoplastic progression","volume":"11","author":"Senapati","year":"2016","journal-title":"Infect. Agents Cancer"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib216","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4081\/oncol.2012.e17","article-title":"Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection","volume":"6","author":"Senba","year":"2012","journal-title":"Oncol. Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib217","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00018-017-2656-0","article-title":"Evaluation and control of MiRNA-like off-Target repression for RNA interference","volume":"75","author":"Seok","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib218","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde.11.155","article-title":"Delivery and biodistribution of SiRNA for cancer therapy: challenges and future prospects","volume":"3","author":"Seth","year":"2012","journal-title":"Ther. Deliv."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib219","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-Based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12985-024-02305-1","article-title":"Mechanisms and consequences of MRNA destabilization during viral infections","volume":"21","author":"Shehata","year":"2024","journal-title":"Virol. J."},{"issue":"17","key":"10.1016\/j.ejphar.2025.178198_bib221","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.jmb.2017.07.018","article-title":"Structural foundations of RNA silencing by argonaute","volume":"429","author":"Sheu-Gruttadauria","year":"2017","journal-title":"J. Mol. Biol."},{"issue":"24","key":"10.1016\/j.ejphar.2025.178198_bib222","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.1039\/D1NR02065J","article-title":"Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery","volume":"13","author":"Shi","year":"2021","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib223","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1261\/rna.073783.119","article-title":"SiRNA potency enhancement via chemical modifications of nucleotide bases at the 5\u2032-End of the SiRNA guide strand","volume":"27","author":"Shinohara","year":"2021","journal-title":"RNA"},{"issue":"20","key":"10.1016\/j.ejphar.2025.178198_bib224","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1093\/nar\/gky745","article-title":"Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified SiRNAs","volume":"46","author":"Shmushkovich","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1478-811X-11-88","article-title":"Exosomes are natural carriers of exogenous SiRNA to human cells in vitro","volume":"11","author":"Shtam","year":"2013","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib226","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.emboj.7601977","article-title":"Messenger RNA regulation: to translate or to degrade","volume":"27","author":"Shyu","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2025.178198_bib227","series-title":"Cellular Experiments to Study the Inhibition of C-Myc\/MAX Heterodimerization","first-page":"193","author":"Singh","year":"2022"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib228","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/cancers11020176","article-title":"Releasing the immune system brakes using SiRNAs enhances cancer immunotherapy","volume":"11","author":"Sioud","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib229","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2004-12-4643","article-title":"RNA interference in biology and disease","volume":"106","author":"Sledz","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib230","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/0109298673278936240107121907","article-title":"Cell-penetrating peptides as keys to endosomal escape and intracellular trafficking in nanomedicine delivery","volume":"32","author":"Soni","year":"2025","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib231","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdq723","article-title":"Epidermal growth factor receptor as a biomarker for cervical cancer","volume":"22","author":"Soonthornthum","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib232","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/onco5010002","article-title":"Dual approaches in oncology: the promise of SiRNA and chemotherapy combinations in cancer therapies","volume":"5","author":"Sousa","year":"2025","journal-title":"Onco"},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib233","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib234","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1093\/nar\/gky437","article-title":"Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis","volume":"46","author":"Stojic","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib235","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/ph16070970","article-title":"Advances with lipid-based nanosystems for SiRNA delivery to breast cancers","volume":"16","author":"Subhan","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2025.178198_bib236","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"36","key":"10.1016\/j.ejphar.2025.178198_bib237","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1038\/sj.onc.1207812","article-title":"Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference","volume":"23","author":"Sumimoto","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2025.178198_bib238","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.omtn.2017.07.008","article-title":"A simple and cost-effective approach for in vitro production of sliced SiRNAs as potent triggers for RNAi","volume":"8","author":"Sun","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178198_bib239","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Contr. Release"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010764","article-title":"\u201cInhibition of ABCB1 (MDR1) Expression by an SiRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma\u201d ed. Benjamin Edward Rich","volume":"5","author":"Susa","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178198_bib241","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2021.694838","article-title":"RNA interference and nanotechnology: a promising alliance for next generation cancer therapeutics","volume":"3","author":"Swaminathan","year":"2021","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.ejphar.2025.178198_bib242","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2019.06.022","article-title":"Chemical modulation of SiRNA lipophilicity for efficient delivery","volume":"307","author":"Tai","year":"2019","journal-title":"J. Contr. Release"},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib243","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/molecules24122211","article-title":"Current aspects of SiRNA bioconjugate for in vitro and in vivo delivery","volume":"24","author":"Tai","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178198_bib244","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.08.004","article-title":"Functional peptides for SiRNA delivery","volume":"110\u2013111","author":"Tai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178198_bib245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.08.004","article-title":"Functional peptides for SiRNA delivery","volume":"110\u2013111","author":"Tai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib246","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-Based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.ejphar.2025.178198_bib247","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178198_bib248","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.45","article-title":"Therapeutic silencing of Bcl-2 by systemically administered SiRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (\u2212) and ER (+) breast cancer","volume":"2","author":"Tekedereli","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.ejphar.2025.178198_bib249","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158787","article-title":"Prognostic impact of epidermal growth factor receptor overexpression in patients with cervical cancer: a meta-analysis","volume":"11","author":"Tian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178198_bib250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight into the prospects for RNAi therapy of cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib251","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"\u201cMechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib252","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/cancers8100095","article-title":"Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites","volume":"8","author":"Tomai\u0107","year":"2016","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib253","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/ph3040961","article-title":"Cell-penetrating peptides\u2014mechanisms of cellular uptake and generation of delivery systems","volume":"3","author":"Trabulo","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"17","key":"10.1016\/j.ejphar.2025.178198_bib254","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/cells13171484","article-title":"HOTAIR promotes the hyperactivation of PI3K\/Akt and Wnt\/\u03b2-Catenin signaling pathways via PTEN hypermethylation in cervical cancer","volume":"13","author":"Trujano-Camacho","year":"2024","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib255","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.molcel.2018.04.010","article-title":"Conformational activation of argonaute by distinct yet coordinated actions of the Hsp 70 and Hsp 90 chaperone systems","volume":"70","author":"Tsuboyama","year":"2018","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib256","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178198_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1447953","article-title":"Exosome-mediated delivery of SiRNA molecules in cancer therapy: triumphs and challenges","volume":"11","author":"Ubanako","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib258","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1093\/nar\/gkac308","article-title":"Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated SiRNA","volume":"50","author":"Uehara","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.178198_bib259","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2012.00101","article-title":"Thermodynamic control of small RNA-mediated gene silencing","volume":"3","author":"Ui-Tei","year":"2012","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib260","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1039\/D0RA07747J","article-title":"Chemical strategies for strand selection in short-interfering RNAs","volume":"11","author":"Varley","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejphar.2025.178198_bib261","doi-asserted-by":"crossref","first-page":"78","DOI":"10.34133\/bmr.0078","article-title":"Navigating latency-inducing viral infections: therapeutic targeting and nanoparticle utilization","volume":"28","author":"Vasukutty","year":"2024","journal-title":"Biomater. Res."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib262","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1128\/JVI.75.9.4467-4472.2001","article-title":"Transcriptional activation of the telomerase HTERT gene by human papillomavirus type 16 E6 oncoprotein","volume":"75","author":"Veldman","year":"2001","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib263","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1476-4598-10-140","article-title":"Papillomavirus E5: the smallest oncoprotein with many functions","volume":"10","author":"Venuti","year":"2011","journal-title":"Mol. Cancer"},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2025.178198_bib264","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.ddtec.2009.02.002","article-title":"PEGylation: posttranslational bioengineering of protein biotherapeutics","volume":"5","author":"Veronese","year":"2008","journal-title":"Drug Discov. Today Technol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/nat.2019.0804","article-title":"Endocytosis controls SiRNA efficiency: implications for SiRNA delivery vehicle design and cell-specific targeting","volume":"30","author":"Vocelle","year":"2020","journal-title":"Nucleic Acid Therapeut."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib266","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/jcm10020220","article-title":"PI3KCA mutations in uterine cervix carcinoma","volume":"10","author":"Voutsadakis","year":"2021","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178198_bib267","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3892\/etm.2010.113","article-title":"SiRNA-Mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo","volume":"1","author":"Wang","year":"2010","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib268","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1208\/s12248-010-9210-4","article-title":"Delivery of SiRNA therapeutics: barriers and carriers","volume":"12","author":"Wang","year":"2010","journal-title":"AAPS J."},{"issue":"18","key":"10.1016\/j.ejphar.2025.178198_bib269","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.62642","article-title":"Effective tools for RNA-derived therapeutics: SiRNA interference or MiRNA mimicry","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib270","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41467-024-45920-w","article-title":"Structure of the P53 degradation complex from HPV16","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178198_bib271","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s000180050296","article-title":"Antisense RNA gene therapy for studying and modulating biological processes","volume":"55","author":"Weiss","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib272","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking Down barriers: advances in SiRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib273","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on SiRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178198_bib274","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003928","article-title":"Immune checkpoint silencing using RNAi-Incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches","volume":"10","author":"Won","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.ejphar.2025.178198_bib275","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ymthe.2023.09.012","article-title":"Optimal delivery of RNA interference by viral vectors for cancer therapy","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib276","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-018-0065-0","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib277","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/630654","article-title":"Dendrimers as carriers for SiRNA delivery and gene silencing: a review","volume":"2013","author":"Wu","year":"2013","journal-title":"Sci. World J."},{"issue":"240","key":"10.1016\/j.ejphar.2025.178198_bib278","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008362","article-title":"RNAi therapies: drugging the undruggable","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib279","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1038\/ncomms4459","article-title":"2\u2032-OMe-Phosphorodithioate-Modified SiRNAs show increased loading into the RISC complex and enhanced anti-tumour activity","volume":"5","author":"Wu","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102437","article-title":"Development, opportunities, and challenges of SiRNA nucleic acid drugs","volume":"36","author":"Xiao","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib281","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12954","article-title":"Insights into the toll\u2010like receptors in sexually transmitted infections","volume":"93","author":"Yadav","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ejphar.2025.178198_bib282","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.10.009","article-title":"Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy","volume":"195","author":"Yamaguchi","year":"2019","journal-title":"Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib283","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000113789","article-title":"SiRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma","volume":"75","author":"Yamanaka","year":"2008","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib284","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202300362","article-title":"Recent advances in engineering carriers for SiRNA delivery","volume":"24","author":"Yang","year":"2024","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib285","article-title":"Comprehensive overview of genotype distribution and prevalence of human papillomavirus in cervical lesions","volume":"4","author":"Ye","year":"2024","journal-title":"Gynecol. Obstetr. Clin. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178198_bib286","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","article-title":"The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis","volume":"37","author":"Yim","year":"2005","journal-title":"Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib287","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89931-9","article-title":"The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells","volume":"11","author":"Yin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.178198_bib288","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in SiRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2025.178198_bib289","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2018.9815","article-title":"CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6","author":"Yoshiba","year":"2018","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.ejphar.2025.178198_bib290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094943","article-title":"HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation","volume":"23","author":"Yu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejphar.2025.178198_bib291","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","article-title":"Development of SiRNA payloads to target KRAS -Mutant cancer","volume":"4","author":"Yuan","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering SiRNA therapeutics: challenges and strategies","volume":"21","author":"Zaidi","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib292","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1172\/JCI81134","article-title":"Extracellular vesicles and intercellular communication within the nervous system","volume":"126","author":"Zappulli","year":"2016","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib293","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-Catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.ejphar.2025.178198_bib294","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41419-023-06377-9","article-title":"Upregulation of FAM83F by C-Myc promotes cervical cancer growth and aerobic glycolysis via Wnt\/\u03b2-Catenin signaling activation","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2025.178198_bib295","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.2147\/IJN.S436038","article-title":"A comprehensive review of small interfering RNAs (SiRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178198_bib296","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf082","article-title":"Strategic base modifications refine RNA function and reduce CRISPR\u2013Cas9 off-targets","volume":"53","author":"Zhang","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178198_bib297","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","article-title":"Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178198_bib298","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.2741\/1971","article-title":"Papillomavirus genome structure, expression, and post-transcriptional regulation","volume":"11","author":"Zheng","year":"2006","journal-title":"Front. Biosci. : J. Vis. Literacy"},{"issue":"27","key":"10.1016\/j.ejphar.2025.178198_bib299","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1016\/j.biomaterials.2012.05.055","article-title":"Enhancing in vivo circulation and SiRNA delivery with biodegradable Polyethylenimine-Graft-Polycaprolactone-Block-Poly(Ethylene glycol) copolymers","volume":"33","author":"Zheng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejphar.2025.178198_bib300","article-title":"Molecular mechanisms of cisplatin resistance in cervical cancer","volume":"1885","author":"Zhu","year":"2016","journal-title":"Drug Des. Dev. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:32:02Z","timestamp":1779323522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":300,"alternative-id":["S0014299925009525"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178198","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small interfering RNA (siRNA) based therapies for cancer treatment: A special focus on cervical cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178198"}}